Hepatitis B vaccine: Further studies in children with previously acquired hepatitis B surface antigenemia

6Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Three doses of inactivated hepatitis B vaccine were given at 1-month intervals to 31 hepatitis B surface antigen (HBsAg)-positive Senegalese children aged between 3 and 24 months. A control group of 18 HbsAg-positive Senegalese children received diphtheria-tetanus-polio vaccine. Immunization of HBsAg-positive infants with hepatitis B vaccine was safe but inefficient. After a 12-month follow-up, the prevalence of HBsAg chronic carriers was not significantly reduced in the hepatitis B vaccine group as compared with the control group: 48.4 and 66.7%, respectively. The presence of hepatitis B antigen was found to be a major risk factor for HBsAg-positive children to develop a chronic carrier state. The risk of developing an HBsAg chronic carrier state was also related to advancing age at time of enrollment in the study.

Cite

CITATION STYLE

APA

Barin, F., Yvonnet, B., Goudeau, A., Coursaget, P., Chiron, J., Denis, F., & Mar, I. D. (1983). Hepatitis B vaccine: Further studies in children with previously acquired hepatitis B surface antigenemia. Infection and Immunity, 41(1), 83–87. https://doi.org/10.1128/iai.41.1.83-87.1983

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free